KPV

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone and retains most of the parent peptide's anti-inflammatory activity while losing its pigmentation and appetite effects. Rather than working through melanocortin receptors on the cell surface, KPV is taken up by intestinal epithelial and immune cells - partly via the PepT1 transporter, which is upregulated exactly where the gut is inflamed - and interferes with NF-kB and AP-1 signalling inside the nucleus. The downstream result in colitis models is lower IL-1beta, IL-6, TNF-alpha and reduced neutrophil infiltration. It also has documented antimicrobial activity against Candida albicans and Staphylococcus aureus, which is part of the rationale for topical use in acne and eczema. All of this is animal and cell-culture work.

Targets: NF-kB, AP-1, PepT1 transporter (intestinal uptake), Pro-inflammatory cytokine transcription

• · The most widely used dose band. Some protocols go to 1000 mcg daily for stubborn inflammatory skin conditions.
• · The PepT1 uptake mechanism is the reason oral dosing is taken seriously here rather than dismissed. Often compounded into a delayed-release capsule to reach the colon.
• · Compounded creams typically run 0.1 to 1 percent KPV for eczema, acne and rosacea.

Work out your exact syringe units →

• commonInjection-site irritation
• uncommonMild flushing
• uncommonHeadache
• rareBlunting of an appropriate immune response— Theoretical, from the mechanism - it is an immunosuppressive signal, so an active untreated infection is not the time to run it.

• Active systemic infection - suppressing NF-kB while you are fighting something is the wrong direction.
• Concurrent immunosuppressive therapy without oversight - the effects are additive in principle.

• synergybpc-157 — The most common oral gut pairing - BPC-157 for mucosal repair, KPV for the inflammatory signal.
• cautionBiologic immunosuppressants — Mechanistically additive immune suppression; no data on the combination.

• · No established bloodwork.
• · For gut use, faecal calprotectin is the objective marker worth tracking if you already have a diagnosis.

Not approved for human use in the US or EU. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend KPV for the 503A Bulks List, alongside BPC-157; the FDA has not yet acted on the recommendation.

• Dalmasso et al. 2008, PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Gastroenterology (preclinical)
• Kannengiesser et al., melanocortin-derived tripeptide KPV in experimental colitis (preclinical)
• FDA Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting materials (guideline)

The interesting thing about KPV is what it does not do. Alpha-MSH works through melanocortin receptors - MC1R for pigmentation, MC4R for appetite, MC3R and MC5R for various inflammatory and exocrine effects. KPV keeps most of the parent's anti-inflammatory activity while losing the tanning and appetite effects, and the reason is that it largely stops using the receptors. Instead, KPV is taken up into cells. In intestinal epithelium and immune cells it enters through PepT1, and once inside it interferes with NF-kB activation and with AP-1 nuclear translocation. That is an intracellular anti-inflammatory action, not a receptor-agonist one, and it explains three things at once: why the anti-inflammatory effect survives when the melanocortin pharmacology is removed, why oral dosing is taken seriously for a tripeptide rather than dismissed, and why the effect concentrates in inflamed gut - because PepT1 is upregulated in inflamed colonic epithelium, the tissue that most needs the drug is the tissue that most efficiently imports it. Downstream, colitis models show reduced IL-1 beta, IL-6 and TNF-alpha and less neutrophil infiltration. That is a broad cytokine suppression rather than a targeted block of one pathway, which is why it reads clinically as a general calming of inflamed tissue rather than as a specific disease-modifying effect. There is a second, separate activity: direct antimicrobial action against Candida albicans and Staphylococcus aureus, which is inherited from alpha-MSH and is part of the rationale for topical use in acne and eczema, where both organisms matter. The clinical shape: fast onset for a compound acting on transcription, one to two weeks for gut and skin symptoms, with the caveat that everything above is mouse and cell culture. There is no completed randomised human trial of KPV for anything.

The main failure is running it into an active infection. KPV suppresses NF-kB, which is the transcription factor your innate immune system uses to mount a response. Doing that during an untreated infection is pushing in the wrong direction, and it is a predicted problem rather than an observed one only because nobody has looked. The second is dosing accuracy. At 200-500 mcg from a 2500 mcg/mL reconstitution you are drawing two to four units on a U-100 syringe. That is a small enough volume that syringe dead space and drawing technique genuinely matter. Reconstitute with more bacteriostatic water if you find yourself squinting at the barrel. The third is expecting it to fix a structural problem. KPV modulates an inflammatory signal. It does not close a fistula, heal a stricture or reverse dysplasia, and using it to feel better while an IBD process advances is how people arrive at surgery with good symptom scores and bad imaging. That is the entire reason calprotectin is in the bloodwork list. The fourth is assuming it is alpha-MSH with the tan removed. It is not a melanocortin agonist at all, so none of the melanotan-family effects - or their side effects - apply, in either direction.

• PepT1 (SLC15A1) intestinal peptide transporter — KPV is a confirmed PepT1 substrate; transport constants not stated here

  Active uptake into intestinal epithelial and immune cells. Not a signalling target - a route of entry, and the reason oral dosing is mechanistically credible.

• NF-kB — Intracellular interference rather than receptor binding

  Blocks activation and nuclear translocation, shutting down transcription of IL-1 beta, IL-6 and TNF-alpha.

• AP-1 — Intracellular interference

  Reduced AP-1 driven inflammatory transcription, complementing the NF-kB effect.

• Melanocortin receptors (MC1R, MC3R, MC4R, MC5R) — Minimal to absent activity at these receptors - this is the defining negative finding

  No pigmentation, no appetite suppression, no libido effect. The entire commercial case for KPV over alpha-MSH analogues rests on this.

• Candida albicans and Staphylococcus aureus — Direct antimicrobial activity, inherited from alpha-MSH

  Growth inhibition, part of the rationale for topical use in acne, eczema and fungal-associated skin conditions.

• No completed randomised human trial of KPV exists for any indication None

  The evidence base is mouse colitis models, cell culture and the PepT1 transport work. This is worth stating plainly because KPV is often described in the same breath as drugs that have been through trials.

Days 1-3: nothing reliable. Injection-site irritation and occasional mild flushing are the only common early reports. Week 1-2: this is when gut and skin symptoms move if they are going to. It is a fast onset for a transcriptional mechanism, which fits an effect on a high-turnover mucosal tissue. Weeks 4-6: the point to check hs-CRP and, for gut use, calprotectin. Symptomatic improvement without a marker change is a signal to be sceptical of. Weeks 6-8: standard course end. Longer continuous use happens in inflammatory bowel contexts and has no safety data behind it whatsoever. Topical: eczema and acne responses are typically described over two to four weeks.

KPV with oral BPC-157 is the most coherent gut stack in this entire class, because the two compounds have genuinely different jobs: BPC-157 for mucosal repair and blood supply, KPV for the inflammatory transcription driving the damage. Both are orally plausible for different reasons - BPC-157 because it survives gastric acid, KPV because PepT1 actively imports it - which is unusual. For the colonic target specifically, a delayed-release capsule matters more than the dose. A tripeptide swallowed as a solution is absorbed in the small intestine by the same transporter that would have carried it into colonic epithelium, so if the target is distal colon you want it to arrive there. Topically, KPV pairs sensibly with anything anti-inflammatory in eczema and rosacea, and its antimicrobial activity against S. aureus is a genuine bonus in eczema where staph colonisation drives flares. The combination to be careful with is any real immunosuppressant - a biologic, azathioprine, systemic steroids. The effects are mechanistically additive and nobody has studied the combination. That is not a reason never to do it, but it is a reason to have the gastroenterologist who prescribed the biologic know about it.

Against mesalazine or a biologic for inflammatory bowel disease: not comparable. Those have large randomised trial bases and defined disease-modifying effects; KPV has mouse models. If you have IBD, KPV is an adjunct to consider alongside real treatment, not an alternative to it. Against BPC-157 for gut symptoms: different targets. BPC-157 repairs mucosa, KPV suppresses the inflammatory signal. In reflux or NSAID damage, BPC-157 is the better-matched tool; in an inflammatory colitis picture, KPV is. Against systemic alpha-MSH analogues such as afamelanotide or melanotan: KPV keeps the anti-inflammatory action and drops the pigmentation, appetite and libido effects entirely, because it is not working through melanocortin receptors. If those effects are what you want, KPV is the wrong compound; if they are what you are trying to avoid, it is exactly the right one. Against topical steroids for eczema: steroids work faster and have decades of data. KPV's argument is that it does not thin skin, so it is a maintenance option rather than a rescue one.

$25–$80/month. Order-of-magnitude estimate for research-chemical vials at 200-500 mcg daily. Compounded delayed-release oral capsules and topical creams from a pharmacy cost considerably more. Not price-checked in the preparation of this entry.

• ?No human pharmacokinetics at all - no tmax, half-life, bioavailability or clearance figure by any route.
• ?No completed randomised human trial for any indication, despite KPV frequently being discussed as though clinical evidence exists.
• ?The 200-500 mcg subcutaneous and 500-1000 mcg oral bands are community convention with no dose-ranging study behind them.
• ?Whether meaningful amounts of orally dosed KPV reach the colon without a delayed-release formulation is unresolved, since PepT1 in the small intestine will absorb it first.
• ?The immunosuppression risk is mechanistically predicted rather than documented; no human study has looked for it.
• ?Whether KPV has any residual melanocortin receptor activity at higher concentrations has not been fully mapped.
• ?Cost figures are estimates and were not price-verified in this session.

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D, Gastroenterology, 2008 · PMID 18061177

  The paper that established the PepT1 uptake mechanism and the NF-kB effect in intestinal epithelium. It is the reason oral KPV is taken seriously rather than dismissed as digestible protein.